Illustration: Gabriella Turrisi/Axios
Carl Icahn didn't mince words in his presentation opposing DNA sequencing giant Illumina's (NYSE: ILMN) quest to own Grail — calling the actions an "existential question" for the company.
Driving the news: The FTC on Monday rejected the deal, saying it will "stifle competition and innovation in the U.S. market."